Khan B, Singer L G, Lilly L B, Chaparro C, Martinu T, Juvet S, Pipkin M, Waddell T K, Keshavjee S, Humar A, Cypel M
Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, Canada.
Toronto Multi-Organ Transplant Program, University of Toronto, Toronto, Canada.
Am J Transplant. 2017 Apr;17(4):1129-1131. doi: 10.1111/ajt.14137. Epub 2017 Jan 16.
Lung transplantation using RNA+ hepatitis C (HCV+) donors to seronegative recipients is not currently performed due to the very high risk of transmission. Previous reports have shown poor survival when this practice was applied. The emergence of new direct-acting antiviral drugs (DAA) suggests a high chance of sustained virologic response in immunocompetent patients. We report here successful transplantation of lungs from HCV+ donor to HCV- recipient. The recipient was an HCV- patient with chronic lung allograft dysfunction. Viral transmission occurred early posttransplant but excellent clinical outcomes were observed including elimination of HCV after 12 weeks of treatment using DAAs.
由于传播风险极高，目前不进行将丙型肝炎病毒核糖核酸阳性（RNA+ 丙肝病毒阳性，HCV+）供体的肺移植给血清学阴性受体的手术。先前的报告显示，采用这种做法时患者生存率较低。新型直接抗病毒药物（DAA）的出现表明，免疫功能正常的患者有很大机会实现持续病毒学应答。我们在此报告了将HCV+ 供体的肺成功移植给HCV- 受体的案例。受体是一名患有慢性肺移植功能障碍的HCV- 患者。病毒在移植后早期发生传播，但观察到了良好的临床结果，包括在使用DAA治疗12周后丙肝病毒被清除。
